Cargando…

Rifaximin‐altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials

AIMS: Rifaximin (RFX), a non‐systemic antibiotic, improves liver/neuropsychological functions in patients with hepatic encephalopathy (HE). We aimed to investigate the clinical profiles associated with gut bacterial loads using exploratory data analysis and the effects of RFX on the gut microbiota o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawaguchi, Takumi, Suzuki, Fumitaka, Imamura, Masatoshi, Murashima, Naoya, Yanase, Mikio, Mine, Tetsuya, Fujisawa, Masaki, Sato, Ikuya, Yoshiji, Hitoshi, Okita, Kiwamu, Suzuki, Kazuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849579/ https://www.ncbi.nlm.nih.gov/pubmed/30589492 http://dx.doi.org/10.1111/hepr.13300

Ejemplares similares

Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis
por: Kaji, Kosuke, et al.
Publicado: (2020)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
por: Kawaratani, Hideto, et al.
Publicado: (2022)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
por: Fujiwara, Yudai, et al.
Publicado: (2021)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Neuropsychological functioning in Wernicke's encephalopathy
por: Behura, Sushree Sangita, et al.
Publicado: (2015)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis
por: Bajaj, J S, et al.
Publicado: (2015)

Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
por: Mangas-Losada, Alba, et al.
Publicado: (2019)

Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
por: Chautant, Fiona, et al.
Publicado: (2020)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy
por: Oey, Rosalie C., et al.
Publicado: (2019)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α
por: Deltenre, Pierre, et al.
Publicado: (2021)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
por: Parisse, Simona, et al.
Publicado: (2023)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
por: Torre, Aldo, et al.
Publicado: (2023)

Neuropsychological, neuroimaging and autopsy findings of butane encephalopathy
por: Yun, Jaeseob, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vdjlttgntvq911sp10v6niv56v